You are here

CB-010

3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond

Motley Fool

Fri, 07/28/23 - 10:38 am

Caribou Biosciences

relapsed or refractory B cell lymphoma

Caribou Scores Early CAR-T Lymphoma Win, Plans $125M Public Offering

BioSpace

Fri, 07/14/23 - 10:03 am

Caribou Biosciences

B-cell non-Hodgkin lymphoma

EHA 2022 preview – some good news at last

EP Vantage

Mon, 05/16/22 - 10:14 am

Caribou Biosciences

ADC Therapeutics